Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:B-cell_ALL
|
| gptkbp:can_lead_to |
infection risk
chronic health issues organomegaly bone marrow failure |
| gptkbp:caused_by |
gptkb:fandom
thrombocytopenia |
| gptkbp:exhibits |
fatigue
weight loss fever lymphadenopathy splenomegaly petechiae |
| gptkbp:genetic_diversity |
gptkb:Philadelphia_chromosome
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ph-positive ALL
|
| gptkbp:is_associated_with |
poor prognosis
immunosuppression increased risk of secondary malignancies increased white blood cell count CNS involvement elevated lactate dehydrogenase poor response to standard therapy |
| gptkbp:is_characterized_by |
gptkb:BCR-ABL_fusion_gene
cytogenetic abnormalities highly aggressive behavior elevated blast count high relapse rate lymphoid blast cells rapidly progressing symptoms |
| gptkbp:is_monitored_by |
complete blood count
|
| gptkbp:is_often_used_in |
adults
certain ethnic groups older adults males certain geographic regions certain familial patterns |
| gptkbp:is_related_to |
gptkb:chronic_myeloid_leukemia
|
| gptkbp:is_studied_in |
clinical trials
genetic research new treatment options |
| gptkbp:occurs_in |
other genetic mutations
|
| gptkbp:scientific_classification |
hematologic malignancy
|
| gptkbp:social_responsibility |
flow cytometry
cytogenetic analysis bone marrow biopsy immunophenotyping |
| gptkbp:treatment |
gptkb:vaccine
supportive care radiation therapy chemotherapy targeted therapy tyrosine kinase inhibitors stem cell transplant novel agents |